Lantus Archives -

Generic drugmaker Viatris has become the first company to secure FDA approval for a biosimilar product that is

FDA okays Viatris’ insulin drug as first ‘interchangeable’ biosimilar

https://pharmaphorum.com/news/fda-okays-mylan-insulin-drug-as-first-interchangeable-biosimilar/

Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but

Sanofi builds case for Toujeo in younger type 1 diabetics

https://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/

Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient

Mylan’s Lantus biosimilar held up by manufacturing issue

https://pharmaphorum.com/news/mylans-lantus-biosimilar-held-up-by-manufacturing-issue/

But sales of key insulin fall amid biosimilar competition.

Sanofi beats expectations, driven by rare diseases and vaccines

https://pharmaphorum.com/news/sanofi-beats-expectations-driven-rare-diseases-vaccines/

Lantus